Navigation Links
KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification
Date:10/15/2009

Martinsried, Leverkusen, Germany, October 15, 2009 / b3c newswire / - KINAXO Biotechnologies GmbH and Bayer Vital GmbH announced today that they will enter into collaboration. KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout for the identification of novel biomarkers in a clinical trial conducted by Bayer Vital.

KINAXOs phosphoproteomics platform allows annotation and quantification of regulated phosphorylation sites. Since the majority of targeted compounds used as anti-cancer drugs influence cellular signal transduction pathways, analysis of phosphorylation patterns in relation to drug administration reveals a compounds molecular mode of action. Characteristic phosphorylation sites predicting response to treatment, resistance mechanism or synergistic effects can hereby be identified as biomarkers which allow for personalized treatment plans.

Accompanying a clinical trial for the multi-kinase inhibitor Nexavar in Acute Myeloid Leukemia (AML), KINAXO will apply its phosphoproteomics technology to reveal the drugs influence on cellular phosphorylation patterns and to search for novel predictive biomarkers. Nexavar is already approved for the treatment of hepatocellular (HCC) and renal cell carcinoma (RCC) and shows promising effects in several other indications, amongst them AML, the most common type of leukemia in adults. Despite considerable efforts over the last decades, therapeutic outcome in AML therapy has improved only modestly and remains dismal, with a high number of patients being non-responsive to standard treatment or recurrent. Application of KINAXOs phosphoproteomics technology could thus turn out to be a valuable tool to discover predictive biomarkers that foretell therapeutic outcome in patients. Furthermore, quantitative phosphoproteomics will be applied to investigate the molecular efficiency of potential combination therapies in which Nexavar will be administered together with other targeted drugs
'/>"/>

b3c newswire

0

GOOD

Page: 1 2 3 4

Related biology news :

1. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
2. KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue
3. VIB and Bayer join forces for plant research
4. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
5. ERS-2 data vital for maritime security
6. New discovery on role of vital protein that fights meningitis
7. Gap junction protein vital to successful pregnancy, researchers find
8. Herbicide-resistant grape could revitalize Midwest wine industry
9. Loggerhead release to provide vital information to scientific community
10. Researchers first to see reactive oxygen species in vital enzyme
11. Understanding phosphorus in soils is vital to proper management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... State University research associate has received a prestigious fellowship ... prevent the spread of malaria. , Bart Bryant, research ... Health,s National Research Service Award Individual Postdoctoral Fellowship, which ... Kansas State University researcher to receive the award and ... such an award. , Bryant, a university doctoral graduate ...
(Date:6/17/2013)... French . A ... Alzheimer,s disease can be reversed with treatment. The study by ... Neuro, at McGill University and at Universit de Montral found ... brain of mice with advanced Alzheimer,s disease (AD) recovers memory ... of Neuroinflammation in May, also suggest an underlying mechanism ...
(Date:6/15/2013)... -- A drug approved in Europe to treat osteoporosis ... breast cancer cells, even in cancers that have become ... Cancer Institute study. , The findings, presented June 15, ... Francisco, indicate that the drug bazedoxifene packs a powerful ... breast cancer cell growth, but also flags the estrogen ...
Breaking Biology News(10 mins):NIH fellowship helps researcher fight malaria, understand mosquito immunity 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors 2
... federal government will spend $21 billion for HIV/AIDS research, ... paying off? A study published in the July 1 ... online, indicates that it is--and more so than previously ... MPH, Kenneth Freedberg , MD, MSc and colleagues at ...
... and ferrets against a highly lethal avian influenza virus, ... St. Jude Children's Research Hospital. The vaccine was developed ... finding, coupled with results of previous studies that showed ... a vaccine would protect humans against multiple variants of ...
... water cycle and havens for wildlife, but they ... collaboration with the Ramsar Convention Secretariat, has been ... provide detailed wide-area views of individual wetlands to ... the success of wetland conservation ultimately comes down ...
Cached Biology News:New study calculates millions of years saved in lives of AIDS patients 2St. Jude test of bird flu vaccine proves successful 2African wetland managers armed with new technology 2
(Date:6/18/2013)... Philadelphia, PA (PRWEB) June 18, 2013 ... fiber-optic Ball Lenses engineered of synthetic Sapphire and Glass ... stock sizes from Swiss Jewel Company , of ... performance by expanding and collimating the light beams without ... extreme optical clarity and natural durability (9 mohs) make ...
(Date:6/18/2013)... , June 18, 2013 ... the release of the HELM biomolecular representation standard ... source MIT licence. HELM (Hierarchical Editing ... wide range of biomolecules (e.g. proteins, nucleotides, antibody ... small-molecule and sequence-based informatics methodologies impractical or unusable. ...
(Date:6/18/2013)... Israel , June 18, 2013 ... Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished ... that the company has been granted a United ... the US and Europe for the ... number 8,410,176 B2 is titled Intermediate Compounds and Processes ...
(Date:6/18/2013)... 2013   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... on discovering breakthrough treatments for human disease, announced ... the company as its vice president of marketing, ... commercial experience to Lexicon, including both pre-launch planning ... areas. Mr. Northcott has held commercial ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3
... NEW YORK, June 5 Crystal Research Associates, ... Informational Overview(R),(EIO(R)) on Arana Therapeutics Ltd. (AAH: ASX). ... http://www.crystalra.com ., Arana Therapeutics Ltd. ("Arana" ... antibody therapeutics to treat,inflammatory diseases and cancer. Arana,s ...
... American Oriental,Bioengineering (NYSE: AOB ) announced today ... The decision to cancel its,convertible preferred stock offering ... conditions resulting in terms that were not acceptable ... Statements made in this press release are forward-looking ...
... Calif., June 5 Exelixis,Inc. (Nasdaq: EXEL ) ... with Deerfield Management, a leading healthcare investment,organization and significant ... in financing through a flexible credit facility. The,funds can ... months at Exelixis,discretion. Exelixis is under no obligation to ...
Cached Biology Technology:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. 3Exelixis Receives $150 Million Funding Commitment From Deerfield Management 2Exelixis Receives $150 Million Funding Commitment From Deerfield Management 3Exelixis Receives $150 Million Funding Commitment From Deerfield Management 4Exelixis Receives $150 Million Funding Commitment From Deerfield Management 5
... PCR Workstation brings together UV irradiation and ... environment against PCR contamination! Quickly inactivate ... Maintain a clean environment with antimicrobial coated ... reagents within minutes with built-in 30-minute timer ...
... Recombinant Enterokinase (rEK) is a highly purified ... enterokinase, a serine protease which recognizes the ... (AspAspAspAspLys?) and has similar enzymatic activity (1). ... and purified to yield the highest activity ...
... of a Hybridizer and UV Crosslinker (254nm UV) ... , This unique, new design for the ... one location , Hybridizer and Crosslinker portions ... , The Crosslinker is also available as ...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
Biology Products: